Valence Discovery
Valence Discovery applies AI-driven generative chemistry to accelerate drug discovery for previously intractable biology targets. The platform uses few-shot learning and proprietary molecular representation techniques to enable rapid end-to-end design of novel chemical matter against complex disease targets.
Series seed of $8.5M (co-led by Fifty Years and Air Street Capital, Feb 2026). Active collaborations with Charles River, Servier, Repare Therapeutics. Built on team's pioneering work in few-shot learning published at NeurIPS, ICLR, ICML.
No products catalogued yet. Press Refresh above to ask the research agent.
People who hold a role here and at another AI company. See the full graph →
No citations stored yet. Run the research agent to attach per-claim sources.